Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis.
We have shown that vaccination with the recombinant N terminus of Als1p (rAls1p-N) protects mice against disseminated and oropharyngeal candidiasis. We now report that vaccination of mice with a related candidate, rAls3p-N, induces a broader antibody response than rAls1p-N and a similar cell-mediated immune response. The rAls3p-N vaccine was equally as effective as rAls1p-N against disseminated candidiasis but was more effective than rAls1p-N against oropharyngeal or vaginal candidiasis. Antibody titers did not correlate with protection against disseminated candidiasis, but delayed-type hypersensitivity did. The rAls3p-N vaccine is a promising new vaccine candidate for further exploration to prevent systemic and mucosal candidal infections.
Spellberg
Brad J
BJ
Department of Medicine, Los Angeles Biomedical Research Institute at Harbor-University of California, Los Angeles (UCLA) Medical Center, Torrance, Torrance, CA 90502, USA. bspellberg@labiomed.org
Ibrahim
Ashraf S
AS
Avanesian
Valentina
V
Fu
Yue
Y
Myers
Carter
C
Phan
Quynh T
QT
Filler
Scott G
SG
Yeaman
Michael R
MR
Edwards
John E
JE
D000818:Animals; D002175:Candida / Q000276:immunology* / Q000302:isolation & purification* / Q000502:physiology; D002177:Candidiasis / Q000097:blood / Q000276:immunology / Q000517:prevention & control* / Q000821:virology*; D005260:Female; D005656:Fungal Proteins / Q000276:immunology*; D005657:Fungal Vaccines / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D011994:Recombinant Proteins
C093538:ALS1 protein, Candida albicans; D005656:Fungal Proteins; D005657:Fungal Vaccines; D011994:Recombinant Proteins